A Phase 1 Study of Pembrolizumab (MK-3475) in Combination With Recombinant Interleukin-12 in Patients With Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 11 Feb 2018
At a glance
- Drugs Interleukin-12 (Primary) ; Pembrolizumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 13 Dec 2017 Planned End Date changed from 1 Sep 2017 to 31 Aug 2020.
- 13 Dec 2017 Planned primary completion date changed from 1 Sep 2017 to 31 Aug 2020.
- 13 Dec 2017 Status changed from not yet recruiting to recruiting.